Huntington's disease (HD) is an inherited neurodegenerative disorder caused by an expanded CAG repeat in the huntingtin (HTT) gene. Its pathogenesis involves mutant huntingtin aggregation, impaired proteostasis and autophagy, transcriptional dysregulation, mitochondrial dysfunction, oxidative stress, neuroinflammation and progressive neuronal loss. Withaferin A (WA), a steroidal lactone derived from Withania somnifera, has demonstrated antioxidant, anti-inflammatory, proteostasis-modulating and stress-response effects in experimental studies. In a transgenic HD mouse model, WA-induced heat-shock-response activation was associated with reduced mutant huntingtin aggregation and attenuation of selected disease-related abnormalities. In contrast, evidence for nuclear factor erythroid 2-related factor 2/antioxidant response element (Nrf2/ARE) activation, autophagy regulation, mitochondrial protection and suppression of inflammatory signaling is derived predominantly from cellular experiments and non-HD neurological or inflammatory models rather than from validated HD models. The direct relevance of these proposed mechanisms to HD therefore remains to be established. No clinical studies have demonstrated the safety or therapeutic efficacy of WA in individuals with HD. Moreover, its bioavailability, pharmacokinetic behavior, optimal dose, long-term toxicity, central nervous system exposure and possible drug interactions remain insufficiently characterized. This review critically evaluates HD-specific and indirect evidence concerning the neuroprotective actions of WA, identifies important methodological and translational limitations and discusses priorities for future investigation. Current evidence supports WA as an experimental compound for further preclinical study rather than as an established or clinically applicable treatment for HD.
